Cargando…
Vascular Dysfunction in Preeclampsia
Preeclampsia is a life-threatening pregnancy-associated cardiovascular disorder characterized by hypertension and proteinuria at 20 weeks of gestation. Though its exact underlying cause is not precisely defined and likely heterogenous, a plethora of research indicates that in some women with preecla...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616535/ https://www.ncbi.nlm.nih.gov/pubmed/34831277 http://dx.doi.org/10.3390/cells10113055 |
_version_ | 1784604372357873664 |
---|---|
author | Opichka, Megan A. Rappelt, Matthew W. Gutterman, David D. Grobe, Justin L. McIntosh, Jennifer J. |
author_facet | Opichka, Megan A. Rappelt, Matthew W. Gutterman, David D. Grobe, Justin L. McIntosh, Jennifer J. |
author_sort | Opichka, Megan A. |
collection | PubMed |
description | Preeclampsia is a life-threatening pregnancy-associated cardiovascular disorder characterized by hypertension and proteinuria at 20 weeks of gestation. Though its exact underlying cause is not precisely defined and likely heterogenous, a plethora of research indicates that in some women with preeclampsia, both maternal and placental vascular dysfunction plays a role in the pathogenesis and can persist into the postpartum period. Potential abnormalities include impaired placentation, incomplete spiral artery remodeling, and endothelial damage, which are further propagated by immune factors, mitochondrial stress, and an imbalance of pro- and antiangiogenic substances. While the field has progressed, current gaps in knowledge include detailed initial molecular mechanisms and effective treatment options. Newfound evidence indicates that vasopressin is an early mediator and biomarker of the disorder, and promising future therapeutic avenues include mitigating mitochondrial dysfunction, excess oxidative stress, and the resulting inflammatory state. In this review, we provide a detailed overview of vascular defects present during preeclampsia and connect well-established notions to newer discoveries at the molecular, cellular, and whole-organism levels. |
format | Online Article Text |
id | pubmed-8616535 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86165352021-11-26 Vascular Dysfunction in Preeclampsia Opichka, Megan A. Rappelt, Matthew W. Gutterman, David D. Grobe, Justin L. McIntosh, Jennifer J. Cells Review Preeclampsia is a life-threatening pregnancy-associated cardiovascular disorder characterized by hypertension and proteinuria at 20 weeks of gestation. Though its exact underlying cause is not precisely defined and likely heterogenous, a plethora of research indicates that in some women with preeclampsia, both maternal and placental vascular dysfunction plays a role in the pathogenesis and can persist into the postpartum period. Potential abnormalities include impaired placentation, incomplete spiral artery remodeling, and endothelial damage, which are further propagated by immune factors, mitochondrial stress, and an imbalance of pro- and antiangiogenic substances. While the field has progressed, current gaps in knowledge include detailed initial molecular mechanisms and effective treatment options. Newfound evidence indicates that vasopressin is an early mediator and biomarker of the disorder, and promising future therapeutic avenues include mitigating mitochondrial dysfunction, excess oxidative stress, and the resulting inflammatory state. In this review, we provide a detailed overview of vascular defects present during preeclampsia and connect well-established notions to newer discoveries at the molecular, cellular, and whole-organism levels. MDPI 2021-11-06 /pmc/articles/PMC8616535/ /pubmed/34831277 http://dx.doi.org/10.3390/cells10113055 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Opichka, Megan A. Rappelt, Matthew W. Gutterman, David D. Grobe, Justin L. McIntosh, Jennifer J. Vascular Dysfunction in Preeclampsia |
title | Vascular Dysfunction in Preeclampsia |
title_full | Vascular Dysfunction in Preeclampsia |
title_fullStr | Vascular Dysfunction in Preeclampsia |
title_full_unstemmed | Vascular Dysfunction in Preeclampsia |
title_short | Vascular Dysfunction in Preeclampsia |
title_sort | vascular dysfunction in preeclampsia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616535/ https://www.ncbi.nlm.nih.gov/pubmed/34831277 http://dx.doi.org/10.3390/cells10113055 |
work_keys_str_mv | AT opichkamegana vasculardysfunctioninpreeclampsia AT rappeltmattheww vasculardysfunctioninpreeclampsia AT guttermandavidd vasculardysfunctioninpreeclampsia AT grobejustinl vasculardysfunctioninpreeclampsia AT mcintoshjenniferj vasculardysfunctioninpreeclampsia |